Healthcare company Organon (NYSE:OGN) announced on Tuesday that it has acquired the US regulatory and commercial rights to TOFIDENCE, a biosimilar to ACTEMRA, from biotechnology company Biogen Inc (Nasdaq:BIIB).
TOFIDENCE, launched in May 2024, is the first FDA-approved tocilizumab biosimilar in the United States. It is indicated for multiple inflammatory conditions, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19.
Under the agreement, Organon gains exclusive US rights to TOFIDENCE in three vial sizes for intravenous infusion, while Bio-Thera Solutions Ltd, the product developer, retains manufacturing rights.
Organon has made an upfront payment to Biogen and will assume Biogen's obligation to pay tiered royalties and annual net sales milestone payments to Bio-Thera Solutions.
This acquisition strengthens Organon's biosimilars portfolio and expands its presence in the US immunology market.
Alphyn doses first patient in Phase 2b trial of Zabalafin Hydrogel in Australia
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
Organon acquires US rights to TOFIDENCE from Biogen
Dupixent receives approval in Japan as first biologic for COPD treatment
Celltrion adds STEQEYMA to Costco Member Prescription Program
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
Spyre Therapeutics starts dosing in Phase 1 clinical trial of SPY003
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Evommune enrols first patient in EVO301 Phase 2 trial
Revelation Biosciences reports Gemini's anti-inflammatory potential in PBMC study
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India
Gentian Diagnostics and Beckman Coulter launch calprotectin immunoassay